139 related articles for article (PubMed ID: 17627490)
1. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics.
Ismail MS; Dagerman K; Tariot PN; Abbott S; Kavanagh S; Schneider LS
Curr Alzheimer Res; 2007 Jul; 4(3):325-35. PubMed ID: 17627490
[TBL] [Abstract][Full Text] [Related]
2. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
[TBL] [Abstract][Full Text] [Related]
3. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
Schneider LS; Ismail MS; Dagerman K; Davis S; Olin J; McManus D; Pfeiffer E; Ryan JM; Sultzer DL; Tariot PN
Schizophr Bull; 2003; 29(1):57-72. PubMed ID: 12908661
[TBL] [Abstract][Full Text] [Related]
4. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.
Mohamed S; Rosenheck R; Lyketsos CG; Kaczynski R; Sultzer DL; Schneider LS
J Clin Psychiatry; 2012 Jan; 73(1):121-8. PubMed ID: 21939611
[TBL] [Abstract][Full Text] [Related]
5. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Schneider LS; Tariot PN; Lyketsos CG; Dagerman KS; Davis KL; Davis S; Hsiao JK; Jeste DV; Katz IR; Olin JT; Pollock BG; Rabins PV; Rosenheck RA; Small GW; Lebowitz B; Lieberman JA
Am J Geriatr Psychiatry; 2001; 9(4):346-60. PubMed ID: 11739062
[TBL] [Abstract][Full Text] [Related]
6. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
[TBL] [Abstract][Full Text] [Related]
7. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
Kirbach S; Simpson K; Nietert PJ; Mintzer J
Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
[TBL] [Abstract][Full Text] [Related]
8. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study.
Nagata T; Nakajima S; Shinagawa S; Plitman E; Nakayama K; Graff-Guerrero A; Mimura M
J Alzheimers Dis; 2017; 60(1):263-272. PubMed ID: 28800334
[TBL] [Abstract][Full Text] [Related]
9. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
10. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.
Nagata T; Shinagawa S; Nakajima S; Plitman E; Mihashi Y; Hayashi S; Mimura M; Nakayama K
J Alzheimers Dis; 2016; 50(3):839-45. PubMed ID: 26836181
[TBL] [Abstract][Full Text] [Related]
11. Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation.
Miller EA; Schneider LS; Rosenheck RA
Int Psychogeriatr; 2011 Feb; 23(1):44-53. PubMed ID: 20214847
[TBL] [Abstract][Full Text] [Related]
12. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
13. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.
Lopez OL; Becker JT; Chang YF; Sweet RA; Aizenstein H; Snitz B; Saxton J; McDade E; Kamboh MI; DeKosky ST; Reynolds CF; Klunk WE
Am J Psychiatry; 2013 Sep; 170(9):1051-8. PubMed ID: 23896958
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation.
Oguma T; Jino K
Chem Pharm Bull (Tokyo); 2024; 72(7):610-617. PubMed ID: 38945937
[TBL] [Abstract][Full Text] [Related]
15. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.
Creese B; Da Silva MV; Johar I; Ballard C
Expert Rev Neurother; 2018 Jun; 18(6):461-467. PubMed ID: 29764230
[TBL] [Abstract][Full Text] [Related]
16. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
Kurlan R; Cummings J; Raman R; Thal L;
Neurology; 2007 Apr; 68(17):1356-63. PubMed ID: 17452579
[TBL] [Abstract][Full Text] [Related]
17. Sociodemographic and clinical correlates of utility scores in Alzheimer's disease.
Miller EA; Schneider LS; Zbrozek A; Rosenheck RA
Value Health; 2008 Dec; 11(7):1120-30. PubMed ID: 18489496
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
[TBL] [Abstract][Full Text] [Related]
19. Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study.
Nagata T; Shinagawa S; Nakajima S; Mimura M; Shigeta M
J Alzheimers Dis; 2018; 66(1):139-148. PubMed ID: 30248052
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly.
Beier MT
Am J Health Syst Pharm; 2007 Jan; 64(2 Suppl 1):S9-17; quiz S24-5. PubMed ID: 17215476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
